Long-term remission of acromegaly after somatostatin analogues withdrawal: a single-centre experience
- Standort
-
Deutsche Nationalbibliothek Frankfurt am Main
- ISSN
-
1720-8386
- Umfang
-
Online-Ressource
- Sprache
-
Englisch
- Anmerkungen
-
online resource.
- Erschienen in
-
Long-term remission of acromegaly after somatostatin analogues withdrawal: a single-centre experience ; day:20 ; month:5 ; year:2021 ; pages:1-7
Journal of endocrinological investigation ; (20.5.2021), 1-7
- Urheber
-
Sala, E.
Carosi, G.
Sindaco, G. Del
Mungari, R.
Cremaschi, A.
Serban, A. L.
Ronchi, C. L.
Ferrante, E.
Arosio, M.
Mantovani, G.
- Beteiligte Personen und Organisationen
-
SpringerLink (Online service)
- DOI
-
10.1007/s40618-021-01562-z
- URN
-
urn:nbn:de:101:1-2021091821560839489662
- Rechteinformation
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Letzte Aktualisierung
-
15.08.2025, 07:33 MESZ
Datenpartner
Dieses Objekt wird bereitgestellt von:
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Beteiligte
- Sala, E.
- Carosi, G.
- Sindaco, G. Del
- Mungari, R.
- Cremaschi, A.
- Serban, A. L.
- Ronchi, C. L.
- Ferrante, E.
- Arosio, M.
- Mantovani, G.
- SpringerLink (Online service)
Ähnliche Objekte (12)
Combined treatment of somatostatin analogues with pegvisomant in acromegaly
Interpreting biochemical control response rates with first-generation somatostatin analogues in acromegaly
Combined therapy of somatostatin analogues with pegvisomant for the treatment of acromegaly: a meta-analysis of prospective studies
Somatostatin Analogues do not Aff ect Calcium Metabolism in Patients with Acromegaly and Primary Hyperparathyroidism due to MEN 1-Like Syndrome
Somatostatin analogues labeled with copper radioisotopes: current status
Somatostatin receptor subtype 2-mediated uptake of radiolabelled somatostatin analogues in the human kidney
Prescription patterns of somatostatin analogs in patients with acromegaly and neuroendocrine tumors
The effects of somatostatin analogue therapy on pituitary tumor volume in patients with acromegaly
Safety review: Dose optimization of somatostatin analogs in patients with acromegaly and neuroendocrine tumors
Acromegaly
Differences in somatostatin receptor subtype expression in patients with acromegaly : new directions for targeted therapy?
Differences in somatostatin receptor subtype expression in patients with acromegaly: new directions for targeted therapy?
Combined treatment of somatostatin analogues with pegvisomant in acromegaly
Interpreting biochemical control response rates with first-generation somatostatin analogues in acromegaly
Combined therapy of somatostatin analogues with pegvisomant for the treatment of acromegaly: a meta-analysis of prospective studies
Somatostatin Analogues do not Aff ect Calcium Metabolism in Patients with Acromegaly and Primary Hyperparathyroidism due to MEN 1-Like Syndrome
Somatostatin analogues labeled with copper radioisotopes: current status
Somatostatin receptor subtype 2-mediated uptake of radiolabelled somatostatin analogues in the human kidney
Prescription patterns of somatostatin analogs in patients with acromegaly and neuroendocrine tumors
The effects of somatostatin analogue therapy on pituitary tumor volume in patients with acromegaly
Safety review: Dose optimization of somatostatin analogs in patients with acromegaly and neuroendocrine tumors
Acromegaly
Differences in somatostatin receptor subtype expression in patients with acromegaly : new directions for targeted therapy?
Differences in somatostatin receptor subtype expression in patients with acromegaly: new directions for targeted therapy?
Combined treatment of somatostatin analogues with pegvisomant in acromegaly
Interpreting biochemical control response rates with first-generation somatostatin analogues in acromegaly
Combined therapy of somatostatin analogues with pegvisomant for the treatment of acromegaly: a meta-analysis of prospective studies
Somatostatin Analogues do not Aff ect Calcium Metabolism in Patients with Acromegaly and Primary Hyperparathyroidism due to MEN 1-Like Syndrome
Somatostatin analogues labeled with copper radioisotopes: current status
Somatostatin receptor subtype 2-mediated uptake of radiolabelled somatostatin analogues in the human kidney
Prescription patterns of somatostatin analogs in patients with acromegaly and neuroendocrine tumors
The effects of somatostatin analogue therapy on pituitary tumor volume in patients with acromegaly
Safety review: Dose optimization of somatostatin analogs in patients with acromegaly and neuroendocrine tumors
Acromegaly
Differences in somatostatin receptor subtype expression in patients with acromegaly : new directions for targeted therapy?